BRPI0407253A - Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos - Google Patents
Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostosInfo
- Publication number
- BRPI0407253A BRPI0407253A BR0407253-7A BRPI0407253A BRPI0407253A BR PI0407253 A BRPI0407253 A BR PI0407253A BR PI0407253 A BRPI0407253 A BR PI0407253A BR PI0407253 A BRPI0407253 A BR PI0407253A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- preparation
- heterocyclyl
- ligands
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
"HETEROCICLIL-3-SULFONILINDAZóIS COMO LIGANDOS 5-HIDROXITRIPTAMINA-6, PROCESSO DE PREPARAçãO DOS MESMOS, SEUS USOS NA PREPARAçãO DE UMA COMPOSIçãO FARMACêUTICA E COMPOSIçãO FARMACêUTICA COMPREENDENDO OS REFERIDOS COMPOSTOS". A presente invenção refere-se a compostos de fórmula (I) e o uso dos mesmos no tratamento terapêutico de distúrbios relacionados com ou afetados pelo receptor 5-HT6.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44761303P | 2003-02-14 | 2003-02-14 | |
PCT/US2004/003926 WO2004074243A2 (en) | 2003-02-14 | 2004-02-10 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0407253A true BRPI0407253A (pt) | 2006-01-31 |
Family
ID=32908471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0407253-7A BRPI0407253A (pt) | 2003-02-14 | 2004-02-10 | Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos |
Country Status (21)
Country | Link |
---|---|
US (3) | US7238696B2 (pt) |
EP (1) | EP1592683A2 (pt) |
JP (1) | JP2006518385A (pt) |
KR (1) | KR20050101551A (pt) |
CN (1) | CN100422171C (pt) |
AR (1) | AR043181A1 (pt) |
AU (1) | AU2004213374A1 (pt) |
BR (1) | BRPI0407253A (pt) |
CA (1) | CA2515570A1 (pt) |
CO (1) | CO5650164A2 (pt) |
CR (1) | CR7930A (pt) |
EC (1) | ECSP055964A (pt) |
MX (1) | MXPA05008438A (pt) |
NO (1) | NO20053792L (pt) |
NZ (1) | NZ541699A (pt) |
PL (1) | PL378120A1 (pt) |
RU (1) | RU2347780C2 (pt) |
TW (1) | TW200505904A (pt) |
UA (1) | UA80184C2 (pt) |
WO (1) | WO2004074243A2 (pt) |
ZA (1) | ZA200506416B (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1293073C (zh) * | 2001-04-20 | 2007-01-03 | 惠氏公司 | 作为5-羟色胺-6配体的杂环基烷氧基-、-烷硫基-和-烷基氨基吲哚衍生物 |
BR0209056A (pt) * | 2001-04-20 | 2004-08-10 | Wyeth Corp | Derivados de heterociclilóxi-, -tióxi- e -aminobenzazol como ligantes de 5-hidroxitriptamina-6 |
RS20060035A (en) | 2003-07-22 | 2008-08-07 | Arena Pharmaceuticals Inc., | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
AU2006280091A1 (en) | 2005-08-15 | 2007-02-22 | Wyeth | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands |
CA2619309A1 (en) * | 2005-08-15 | 2007-03-22 | Wyeth | Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands |
MX2008009022A (es) * | 2006-01-13 | 2008-09-24 | Wyeth Corp | 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina. |
PE20071143A1 (es) * | 2006-01-13 | 2008-01-20 | Wyeth Corp | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
JP5255559B2 (ja) * | 2006-03-31 | 2013-08-07 | アボット・ラボラトリーズ | インダゾール化合物 |
MX2008012824A (es) * | 2006-04-05 | 2008-10-15 | Wyeth Corp | Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6. |
WO2007120596A1 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS |
PT2040755E (pt) * | 2006-06-23 | 2011-07-08 | Esteve Labor Dr | Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6 |
EP2158195A1 (en) | 2007-05-15 | 2010-03-03 | Wyeth LLC | 5- (aminoazacyclyl) -3-sulfonyl-lh- indazoles as 5-hydroxytryptamine- 6 ligands for the treatment of cns disorders |
US20090012308A1 (en) * | 2007-06-13 | 2009-01-08 | Wyeth | Process for the manufacture of benzylsulfonylarenes |
WO2009074607A1 (en) | 2007-12-12 | 2009-06-18 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
WO2009155399A1 (en) * | 2008-06-20 | 2009-12-23 | Wyeth | 1-substituted-3-(naphthalen-1-ylsulfonyl)-5-(piperazin-1-yl)-1h-indazole compounds as 5-hydroxytryptamine-6 ligands |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
US8518933B2 (en) * | 2009-04-23 | 2013-08-27 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
ES2568262T3 (es) * | 2009-04-23 | 2016-04-28 | Abbvie Inc. | Moduladores de receptores de 5-HT y sus métodos de uso |
CN105541693B (zh) | 2014-07-08 | 2018-10-16 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物上的应用 |
AU2015341913B2 (en) | 2014-11-03 | 2020-07-16 | Iomet Pharma Ltd | Pharmaceutical compound |
CN104693186B (zh) * | 2014-12-31 | 2017-12-22 | 青岛黄海制药有限责任公司 | 一种吲哚衍生物中c‑f键生成c‑n键合成西泮类药物的方法 |
CN109562085A (zh) | 2015-06-12 | 2019-04-02 | 阿速万科学有限责任公司 | 用于预防和治疗rem睡眠行为障碍的二芳基和芳基杂芳基脲衍生物 |
AU2016291673A1 (en) | 2015-07-15 | 2018-01-25 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
WO2021262587A1 (en) | 2020-06-22 | 2021-12-30 | Corcept Therapeutics Incorporated | Quaternary indazole glucocorticoid receptor antagonists |
WO2023122600A1 (en) * | 2021-12-21 | 2023-06-29 | Corcept Therapeutics Incorporated | Piperazine indazole glucocorticoid receptor antagonists |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR008245A1 (es) * | 1996-06-21 | 1999-12-29 | Glaxo Group Ltd | Derivados de acido acetico, uso de los mismos en la fabricacion de un agente terapeutico y proceso para preparar dichos derivados |
EA200000488A1 (ru) | 1997-11-04 | 2000-10-30 | Пфайзер Продактс Инк. | Замена катехина на биоизостеру индазола в терапевтически активных соединениях |
EP1343756A2 (en) | 2000-11-02 | 2003-09-17 | Wyeth | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
DK1355904T3 (da) | 2000-12-22 | 2007-10-15 | Wyeth Corp | Heterocyclindazol- og -azaindazolforbindelser som 5-hydroxytryptamin-6-ligander |
CN1492863A (zh) | 2000-12-22 | 2004-04-28 | 作为5-羟色胺-6配基的杂环基烷基-吲哚或氮杂吲哚化合物 | |
TW593278B (en) | 2001-01-23 | 2004-06-21 | Wyeth Corp | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
BR0209056A (pt) * | 2001-04-20 | 2004-08-10 | Wyeth Corp | Derivados de heterociclilóxi-, -tióxi- e -aminobenzazol como ligantes de 5-hidroxitriptamina-6 |
CN1293073C (zh) | 2001-04-20 | 2007-01-03 | 惠氏公司 | 作为5-羟色胺-6配体的杂环基烷氧基-、-烷硫基-和-烷基氨基吲哚衍生物 |
WO2002100833A1 (fr) | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Inhibiteurs de rho kinase |
EP1414442A1 (en) | 2001-08-07 | 2004-05-06 | Smithkline Beecham Plc | 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders |
US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
DE60309852T2 (de) | 2002-03-27 | 2007-06-06 | Glaxo Group Ltd., Greenford | Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden |
PL209872B1 (pl) | 2002-03-27 | 2011-10-31 | Glaxo Group Ltd | Pochodna chinolinowa, sposób jej wytwarzania i jej zastosowanie oraz zawierająca ją farmaceutyczna kompozycja |
TW200400177A (en) | 2002-06-04 | 2004-01-01 | Wyeth Corp | 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands |
JP4754821B2 (ja) | 2002-06-20 | 2011-08-24 | プロキシマゲン・リミテッド | 肥満症、ii型糖尿病およびcns障害の治療に有用な新規化合物 |
TW200401641A (en) | 2002-07-18 | 2004-02-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands |
TW200403243A (en) | 2002-07-18 | 2004-03-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
CA2515571A1 (en) | 2003-02-14 | 2004-09-02 | Wyeth | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
DE102004046356A1 (de) * | 2004-09-24 | 2006-03-30 | Clariant Gmbh | Verfahren zur Herstellung von Alk(en)ylphosphorsäureestersalzen |
-
2004
- 2004-02-10 RU RU2005128556/04A patent/RU2347780C2/ru active
- 2004-02-10 AU AU2004213374A patent/AU2004213374A1/en not_active Abandoned
- 2004-02-10 MX MXPA05008438A patent/MXPA05008438A/es active IP Right Grant
- 2004-02-10 KR KR1020057014910A patent/KR20050101551A/ko not_active Application Discontinuation
- 2004-02-10 WO PCT/US2004/003926 patent/WO2004074243A2/en active Application Filing
- 2004-02-10 EP EP04709911A patent/EP1592683A2/en not_active Withdrawn
- 2004-02-10 CN CNB2004800094268A patent/CN100422171C/zh not_active Expired - Fee Related
- 2004-02-10 TW TW093103031A patent/TW200505904A/zh unknown
- 2004-02-10 BR BR0407253-7A patent/BRPI0407253A/pt not_active IP Right Cessation
- 2004-02-10 JP JP2006503466A patent/JP2006518385A/ja not_active Ceased
- 2004-02-10 PL PL378120A patent/PL378120A1/pl unknown
- 2004-02-10 NZ NZ541699A patent/NZ541699A/en unknown
- 2004-02-10 CA CA002515570A patent/CA2515570A1/en not_active Abandoned
- 2004-02-13 US US10/778,427 patent/US7238696B2/en not_active Expired - Fee Related
- 2004-02-13 AR ARP040100459A patent/AR043181A1/es unknown
- 2004-10-02 UA UAA200508735A patent/UA80184C2/uk unknown
-
2005
- 2005-08-03 CR CR7930A patent/CR7930A/es not_active Application Discontinuation
- 2005-08-10 CO CO05079298A patent/CO5650164A2/es not_active Application Discontinuation
- 2005-08-10 NO NO20053792A patent/NO20053792L/no not_active Application Discontinuation
- 2005-08-11 ZA ZA200506416A patent/ZA200506416B/xx unknown
- 2005-08-11 EC EC2005005964A patent/ECSP055964A/es unknown
-
2007
- 2007-05-15 US US11/803,531 patent/US7560470B2/en not_active Expired - Fee Related
-
2009
- 2009-06-12 US US12/483,344 patent/US20090253711A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20050101551A (ko) | 2005-10-24 |
AR043181A1 (es) | 2005-07-20 |
CA2515570A1 (en) | 2004-09-02 |
WO2004074243A2 (en) | 2004-09-02 |
ZA200506416B (en) | 2007-02-28 |
NZ541699A (en) | 2009-01-31 |
RU2347780C2 (ru) | 2009-02-27 |
NO20053792L (no) | 2005-08-10 |
CR7930A (es) | 2006-02-07 |
PL378120A1 (pl) | 2006-03-06 |
CO5650164A2 (es) | 2006-06-30 |
US20070232618A1 (en) | 2007-10-04 |
EP1592683A2 (en) | 2005-11-09 |
US20040167122A1 (en) | 2004-08-26 |
US20090253711A1 (en) | 2009-10-08 |
WO2004074243A3 (en) | 2004-12-02 |
US7238696B2 (en) | 2007-07-03 |
AU2004213374A1 (en) | 2004-09-02 |
CN1771244A (zh) | 2006-05-10 |
TW200505904A (en) | 2005-02-16 |
ECSP055964A (es) | 2006-01-16 |
UA80184C2 (en) | 2007-08-27 |
JP2006518385A (ja) | 2006-08-10 |
RU2005128556A (ru) | 2006-01-27 |
CN100422171C (zh) | 2008-10-01 |
US7560470B2 (en) | 2009-07-14 |
MXPA05008438A (es) | 2005-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0407253A (pt) | Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos | |
BR0309167A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afetado por uma condição patológica ou doença e produto de combinação | |
BRPI0614168A2 (pt) | Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto | |
BRPI0519280A2 (pt) | composto, composiÇço farmacÊutica e uso de um composto | |
BRPI0510453A (pt) | composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central | |
BRPI0417323A (pt) | indóis, 1h-indazóis, 1,2-benzisoxazóis, e 1,2-benzisotiazóis, composto, composição farmacêutica e usos dos mesmos | |
BRPI0418099A (pt) | compostos, composição farmacêutica, e uso de um composto | |
BR0206633A (pt) | Derivados de 1-aril- ou 1-arilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6 | |
BRPI0618552B8 (pt) | compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos | |
NO20093464L (no) | Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika | |
BR0116323A (pt) | Compostos de heterociclilindazol e -azaindazol como ligandos de 5-hidroxitriptamina-6 | |
UA83862C2 (ru) | Производные тиазола как модуляторы рецепторов канабиноидов | |
BRPI0408681A (pt) | compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos | |
NO20092529L (no) | Substituerte 2,3-dihydroimidazo[1,2-c]kinazolinderivater som er anvendbare for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese | |
BRPI0510664B8 (pt) | derivados de fenol e tiofenol 3 ou 4-monosubstituído, composição farmacêutica, combinação e uso dos compostos para tratamento de doenças relacionadas ao h3, incluindo transtornos do sistema nervoso central e transtornos inflamatórios | |
BR0206435A (pt) | Composto, composição farmacêutica, métodos de tratar a angiogênese em um paciente, de tratar distúrbios relacionados com kdr e proliferativos em um mamìfero, uso de um composto, e, processo para preparar compostos | |
NO20075623L (no) | Benzodioksan- og benzodioksolanderivater og deres anvendelse | |
BRPI0511874A (pt) | derivados da pirrolopiridina | |
BRPI0417833A (pt) | novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6 | |
BR0214243A (pt) | Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida | |
BR0209056A (pt) | Derivados de heterociclilóxi-, -tióxi- e -aminobenzazol como ligantes de 5-hidroxitriptamina-6 | |
BR0116481A (pt) | Compostos de heterociclilalquilindol ou azaindol como ligandos de 5-hidroxitriptamina-6 | |
BR0215222A (pt) | Derivados de indolilalquilamina como ligantes de 5-hidroxitriptamina-6 | |
BRPI0713443A2 (pt) | Derivados de piperazinila úteis no tratamento de doenças medianas por receptor gpr38, uso e composição farmacêutica contendo tais compostos e processos para preparação dos mesmos | |
BRPI0412809A (pt) | compostos de sulfonildihidrobenzimidazolona como ligantes a 5-hidróxitriptamina-6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |